Identification of a novel route of extraction of sirolimus in human small intestine: Roles of metabolism and secretion

Journal of Pharmacology and Experimental Therapeutics

Volumn 301, Issue 1, 2002, Pages 174-186

  Paine, Mary F ^a   Leung, Louis Y ^b   Lim, H K ^b,d   Liao, Kecheng ^b   Oganesian, Aram ^b   Zhang, Mei Yi ^b   Thummel, Kenneth E ^c   Watkins, Paul B ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; GLYCOPROTEIN P; KETOCONAZOLE; RAPAMYCIN; TROLEANDOMYCIN; ZOSUQUIDAR;

APICAL MEMBRANE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ELIMINATION; DRUG ISOLATION; DRUG METABOLISM; DRUG TRANSPORT; FIRST PASS EFFECT; HUMAN; HUMAN CELL; INTESTINE MUCOSA; MEMBRANE PERMEABILITY; MICROSOME; PRIORITY JOURNAL; SMALL INTESTINE;

ALGORITHMS; BLOTTING, WESTERN; CACO-2 CELLS; CARRIER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINE, SMALL; KINETICS; MICROFILAMENT PROTEINS; MIXED FUNCTION OXYGENASES; P-GLYCOPROTEIN; SIROLIMUS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBCELLULAR FRACTIONS;

EID: 0036193375     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.301.1.174     Document Type: Article

References (40)

1. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond
2. Monoclonal antibodies against human liver cytochrome P-450
3. Clinically significant drug interactions with cyclosporin. An update
4. Mass spectrometric characteristics of the immunosuppressive agent rapamycin
5. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin
6. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities
7. St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
8. Species differences in sirolimus stability in humans, rabbits, and rats
9. Population pharmacokinetics of sirolimus in kidney transplant patients
10. 3-modified Caco-2 cell monolayers
11. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
12. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells
13. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
14. Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry
15. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4
16. P- glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4
17. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation
18. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
19. Cyclosporine metabolism by P450IIIA in rat enterocytes-another determinant of oral bioavailability?
20. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs
21. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine
22. Sirolimus (rapamycin): Metabolite characterization in rat and human liver microsomal incubation, and in trough whole blood of renal transplant patients treated with sirolimus, cyclosporine and prednisone
23. 14C-rapamycin (sirolimus) in healthy male subjects after a single oral dose
24. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test
25. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
26. Protein measurement with the folin phenol reagent
27. The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications
28. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism
29. Clinical pharmacokinetics of cyclosporin
30. Acute heart transplant rejection due to Saint John's wort
31. Human P-glycoprotein transports cyclosporin A and FK506
32. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
33. 3
34. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
35. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
36. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
37. Clinical pharmacokinetics of tacrolimus
38. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
39. High performance liquid chromatographic isolation, spectroscopic characterisation, and immunosuppressive activities of two rapamycin degradation products
40. Rapamycin: Distribution, pharmacokinetics, and therapeutic range investigations